Blacksburg-based Intrexon filed forms with the Securities and Exchange Commission on Tuesday that lay the groundwork for the biotechnology company to pursue an initial public offering.

Regulatory documents show the firm hopes to raise a maximum of $125 million in the offering, though that figure is primarily used to determine the registration fee and is subject to change.

The exact per-share price and number of shares to be sold were not provided. The company declined to comment beyond its S-1 filing.

Intrexon, which has a large office in Germantown, collaborates with other companies in sectors such as medicine, animal science and agriculture to engineer biological products and processes.

The firm had revenue of $13.9 million at the end of 2012, according the regulatory filing, up from $8.2 million the year before. In 2012, Intrexon posted a net income loss of $81.9 million.

The company has attracted gobs of investment dollars in recent years. In May, the firm raised $150 million from its financial backers, bringing its total venture capital to $509 million.

Follow Steven Overly on Twitter: @StevenOverly